Member Info for Bella6532

Cautious...that was my understanding...Medusa will be assembling not producing all components from scratch. Now where are Mologic getting their strips from? Are they producing them? If so it looks like they are the only ones to do so right now. If Abingdon are now producing them then Mologic surely will be able to take supply and start assembling now too.

As we all know there are supply issues in the UK so let's hope all the components are getting through and production is able to be geared up. I still suspect it was a component supply issue that caused the hiccup with Mologic.
If all parts are produced in the UK then that's not a problem...if parts have to come in from overseas it could be...shipping Co trainer issues.. truck driver and customs issues...

Fingers crossed Avacta and their partners are now confident they will be able to meet the needs of their customers and will be shortly or are already taking orders for professional use...as with Calibre they can take orders in advance of production/assembly initially.

Cautious...that was my understanding...Medusa will be assembling not producing all components from scratch. Now where are Mologic getting their strips from? Are they producing them? If so it looks like they are the only ones to do so right now. If Abingdon are now producing them then Mologic surely will be able to take supply and start assembling now too.

As we all know there are supply issues in the UK so let's hope all the components are getting through and production is able to be geared up. I still suspect it was a component supply issue that caused the hiccup with Mologic.
If all parts are produced in the UK then that's not a problem...if parts have to come in from overseas it could be...shipping Co trainer issues.. truck driver and customs issues...

Fingers crossed Avacta and their partners are now confident they will be able to meet the needs of their customers and will be shortly or are already taking orders for professional use...as with Calibre they can take orders in advance of production/assembly initially.

Zoom001...does Medusa actually manufacture or do they outsource this...there's a big difference.

Cautious...'Admittedly this presently relates to the Rapid Saliva Protein Test, not AffiDx, but gives an idea of the minimum scale of operation Medusa19 are targeting. I suspect the moment they launch AffiDx, they’ll be set up to provide it at large scale.'

Is it possible some of the Mologic production has been put into stock ready for the Medusa launch. The NMF is for Avacta professional use so should they want to purchase the Avacta LFT thru Medusa they can do so and it can ship from which ever location it is in stock. The coming soon on the Medusa website surely just refers to home use orders from joe blow.
Any orders from Govt would surely be transacted via separate contact details lodged with the application etc...

The reason I say this is because of comments made regarding guaranteed supply to Calibre and they started shipping again yesterday from new stock.

I just feel there's been a upshift within our production and everything is now finally starting to be pulled together...niggles etc ironed out...

appletree1...they do look like they could be part of a big order being filled...

On investing they're showing as buys...

russell1...microinvesting platforms...free trading mobile sites...change investing linked to spending...etc etc...perhaps...

Russell1...mobile free trading sites?
Also some sites nowadays allow you to trade spare cash in your account/bank account automatically if you set it up to do so.

Couldn't log into LSE this morning until now...anyone else had problems?

Timster...haha..yes you could be right...last year they gave just 2 weeks notice (14 Sept for 28 Sept)...

'Overall, Affimer 780A represents a first-in-class selective binder for EPAC1 for use in biochemical and cell
biology studies of cyclic AMP signaling. Future work will be aimed at improving the affinity of Affimer A780 towards EPAC1 through selective mutation of the Affimer binding site and also generate Affimers to the N- and C-termini of EPAC1. By improving the affinity towards EPAC1 and identifying further interactions sites we hope to extend the usefulness of EPAC1 Affimers for fluorescent microscopy and other applications, including modulation of EPAC1 activity and intracellular targeting.'

Funding: This research was jointly funded by Medical Research Scotland (grant number: PhD-868-
2015) and Avacta Life Sciences, through a studentship awarded to H.K.B. U.L.S. was a British Heart
Foundation research scholar (grant number FS/17/12/32703). B.V.B. was funded by a James Watt
Research Scholarship, funded by Heriot-Watt University.

She is our legal trademark representative handling it stateside.
https://www.stites.com/attorneys/alexandra-mackay

Thanks MM
I suspect it's been a combination of several factors.
1. Production ramp up
2. Decision to set aside some production as back up stock just in case there's a batch failure (which does happen)/machinery breakdown/supply hiccup etc.
3. Another production site TT transfer awaited.

for Avacta to give Calibre such a strong reassurance all or most of the above must have now taken place.

As you know most manufacturers work on a Just In Time basis and rely on their Stocking Distributor networks to service their defined marketplace. However, with new product launches, there are often hiccups within the supply chain, manufacturing and/or Distributor stock availability. It's a learning curve for everyone involved and nothing to be too concerned about.

Onward and upward from Monday....

So where are we at with regard to developing rapid tests for other diseases through our collaboration with Mologic? – surely work done back in 2016 etc puts us streets ahead and can this now be combined with the fact Mologic helped us get our test approved so both companies can now move forward with their collaboration on tests for other diseases…
22 Jun 2016
https://avacta.com/avacta-rapidly-generates-affimer-binders-zika-virus-diagnostics/
‘The ability to rapidly generate new diagnostic reagents in response to outbreaks of infectious agents is critical to meeting an urgent medical need, as recently evidenced by the SARS and Ebola virus outbreaks. The very high specificity of Avacta’s Affimer technology, together with the speed with which new Affimer binders can be identified and characterised, makes the technology ideal for rapidly responding to the need for detection and monitoring of new outbreaks. The Group intends to commercialise Affimer based rapid diagnostics through co-development and licensing to third party diagnostics developers an example of which is Mologic, a UK rapid diagnostics developer, with whom a research and product development collaboration was recently announced.’

8 Feb 2021 This sentence was in the Avacta/Mologic Commercial Partnership RNS:
‘The partnership between Avacta and Mologic also provides a framework agreement for the future development of a pipeline of tests in a range of disease areas.’

19 July 2021 we have the news:
‘Philanthropists George Soros and Bill Gates are part of a consortium buying a UK developer of testing technology (Mologic) they plan to transform into a social enterprise that can quickly and cheaply diagnose tropical diseases in low-income countries.’

If there new production comes on stream/ there's a significant ramp up then surely this should be RNS worthy as it will significantly affect the financial position if the company.

It's a simple service address...
https://mtmlegal.co.uk/address-mail-services/

Not at all Agent B...two different markets and both sides of the company now growing so each needs its own handler with specific knowledge, contacts and skills...

String of large trades (buys) yesterday out of the blue and SP didn't react accordingly...and this morning we get this great appointment...mmm!
Of course I'm not saying someone knew this was coming..that would be a ridiculous assumption, wouldn't it...lol!!!

This says it all really...
'I look forward to the opportunity of driving the strategic leadership of the company's therapeutics research and am excited by the potential of the pre|CISION™ and Affimer® platforms, to develop first and best-in-class oncology therapeutics, to ultimately provide patients with important new treatment options.'

Russell1 yes, this one:
01-Sep-21 13:31:02 133.50 110,000 Buy* 131.00 134.00 146.85k

and then this?
01-Sep-21 14:35:55 133.00 150,000 Buy* 131.00 133.00 199.50k O

Ouch they didn't exactly get mates rates...lol!!!